[go: up one dir, main page]

AU2003270009A1 - Oral delivery of modified transferrin fusion proteins - Google Patents

Oral delivery of modified transferrin fusion proteins

Info

Publication number
AU2003270009A1
AU2003270009A1 AU2003270009A AU2003270009A AU2003270009A1 AU 2003270009 A1 AU2003270009 A1 AU 2003270009A1 AU 2003270009 A AU2003270009 A AU 2003270009A AU 2003270009 A AU2003270009 A AU 2003270009A AU 2003270009 A1 AU2003270009 A1 AU 2003270009A1
Authority
AU
Australia
Prior art keywords
fusion proteins
oral delivery
transferrin fusion
modified transferrin
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003270009A
Other versions
AU2003270009A8 (en
Inventor
Christopher P. Prior
Homayoun Sadeghi
Andrew Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biorexis Pharmaceutical Corp
Original Assignee
Biorexis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/378,094 external-priority patent/US7176278B2/en
Application filed by Biorexis Pharmaceutical Corp filed Critical Biorexis Pharmaceutical Corp
Publication of AU2003270009A1 publication Critical patent/AU2003270009A1/en
Publication of AU2003270009A8 publication Critical patent/AU2003270009A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70582—CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2003270009A 2002-08-30 2003-08-28 Oral delivery of modified transferrin fusion proteins Abandoned AU2003270009A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US40697702P 2002-08-30 2002-08-30
US60/406,977 2002-08-30
US10/378,094 2003-03-04
US10/378,094 US7176278B2 (en) 2001-08-30 2003-03-04 Modified transferrin fusion proteins
US46082903P 2003-04-08 2003-04-08
US60/460,829 2003-04-08
PCT/US2003/026778 WO2004019872A2 (en) 2002-08-30 2003-08-28 Oral delivery of modified transferrin fusion proteins

Publications (2)

Publication Number Publication Date
AU2003270009A1 true AU2003270009A1 (en) 2004-03-19
AU2003270009A8 AU2003270009A8 (en) 2004-03-19

Family

ID=31982316

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003270009A Abandoned AU2003270009A1 (en) 2002-08-30 2003-08-28 Oral delivery of modified transferrin fusion proteins

Country Status (2)

Country Link
AU (1) AU2003270009A1 (en)
WO (1) WO2004019872A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2005271403A1 (en) * 2004-08-03 2006-02-16 Biorexis Pharmaceutical Corporation Combination therapy using transferrin fusion proteins comprising GLP-1
ES2371495T3 (en) 2006-07-24 2012-01-03 Biorexis Pharmaceutical Corporation EXENDINE FUSION PROTEINS.
WO2008033395A2 (en) * 2006-09-14 2008-03-20 Biorexis Pharmaceutical Corporation Melanocortin and transferrin fusion proteins
AU2007331195A1 (en) 2006-12-12 2008-06-19 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20090181048A1 (en) * 2007-06-08 2009-07-16 The Regents Of The University Of California Cancer drug delivery using modified transferrin
US20110288023A1 (en) * 2007-06-08 2011-11-24 The Regents Of The University Of California Office Of Technology Transfer Cancer drug delivery using modified transferrin
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US10513563B2 (en) * 2010-07-02 2019-12-24 University Of Southern California Method for uses of proinsulin transferrin fusion proteins as prodrugs
US20120004398A1 (en) * 2010-07-02 2012-01-05 University Of Southern California Method for Uses of Protein Precursors as Prodrugs
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
SI2646470T1 (en) 2010-11-30 2017-05-31 F. Hoffmann-La Roche Ag Low affinity anti-transferrin receptor antibodies and their use to transfer therapeutic scfv across the blood brain barrier
FR2994657A1 (en) * 2012-08-23 2014-02-28 Henri Allain NEW APPLICATIONS AND USES OF LACTOFERRIN
CA2902348C (en) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HK1220611A1 (en) 2013-03-15 2017-05-12 Bausch Health Ireland Limited Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2015054649A2 (en) 2013-10-10 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
EP3402804A1 (en) 2016-01-11 2018-11-21 Synergy Pharmaceuticals Inc. Formulations and methods for treating ulcerative colitis
US11753455B2 (en) 2018-06-21 2023-09-12 Novo Nordisk A/S Compounds for treatment of obesity
CN112516168B (en) * 2020-12-11 2022-07-26 中国人民解放军军事科学院军事医学研究院 Mesenchymal stem cells for intervention in stress-induced cognitive impairment
CN120192428B (en) * 2025-03-21 2025-12-05 西安宝诗特尔科学研究有限公司 Recombinant proteins, DNA fragments, expression vectors, methods for preparing transgenic lettuce, and oral hypoglycemic drugs

Also Published As

Publication number Publication date
WO2004019872A2 (en) 2004-03-11
AU2003270009A8 (en) 2004-03-19
WO2004019872A3 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
AU2003270009A1 (en) Oral delivery of modified transferrin fusion proteins
IL166750A0 (en) Modified transferrin fusion proteins
AU2003210806A1 (en) Heterologous g-csf fusion proteins
AU2003239365A1 (en) Recombinant glycosyltransferase fusion proteins
IL166751A0 (en) Modified transferin-antibody fusion proteins
WO2004040000A9 (en) G protein coupled receptors and uses thereof
AU2003209475A1 (en) Fast melt multiparticulate formulations for oral delivery
AU2003228364A1 (en) Field-assisted fusion bonding
AU2002353921A1 (en) Proteins stabilized with polysaccharide gums
AU2002362710A1 (en) Use of thymulin-like peptides for making pain-relieving medicines
AU2003289742A1 (en) Stable therapeutic proteins
AU2003201727A1 (en) Recombinant protein expression
AU2003251797A1 (en) Methods and compositions for the production, identification and purification of fusion proteins
AU2003226899A1 (en) Human diabetes-mediating proteins
AU2002251972A1 (en) Fusion proteins based upon somatostatin receptors
AU2003272423A1 (en) Centrosome proteins and uses thereof
AU2003240974A1 (en) Human prolactin antagonist-angiogenesis inhibitor fusion proteins
GB0200689D0 (en) Fusion proteins
AU2002308649A1 (en) Compositions and methods for enhancing drug delivery
AU2002361963A1 (en) Fusion proteins containing tlp peptides
AU2003215452A1 (en) Surface proteins of leptospira
EP1581250A4 (en) Oral formulations for proteins and polypeptides
AU2003280992A1 (en) Novel proteins and use thereof
AU2003254001A1 (en) Novel htnfsf13b protein variants
AU2003220085A1 (en) Protein a compositions and methods of use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase